BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New US Patent Grant for ValiRx Plc's Cancer Screening Gene Biomarker


5/15/2012 9:42:39 AM

15 May 2012 -- ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that a method for cancer screening, using specific gene biomarkers in the field of genetics and oncology, has recently received patent approval by the United States' patent office.

The granting of this latest patent means that ValiRx now has biomarker patent protection in both the US and across Europe, alongside granted and pending patents for its therapeutic technologies across Europe, the US, Canada and Australia.

This latest patent concerns the method or process by which gene biomarkers can be used in the detection or identification of a patient’s susceptibility to cutaneous T-cell lymphoma (a type of non-Hodgkin’s lymphoma) and also for improving treatment methods.

The use of biomarkers in oncology therapeutics is one of the fastest growing areas in cancer diagnosis and monitoring. In combination with specific therapeutic approaches, it is the growth of personalised medicine, particularly in cancer research, alongside support from regulatory agencies that are the key factors behind the increase in demand for biomarkers.

Personalised therapeutics are gaining popularity due to their ability to provide customised treatment to patients based on their genetic and medical profile. Since biomarkers help in predicting patient response to a compound, personalised medicines are increasingly using biomarkers to identify the patient population set that is more likely to respond to a particular drug therapy. Personalised medicines are also increasingly being used along with targeted cancer therapies and as personalised medicines gain more importance and popularity, the demand for suitable companion biomarkers is also expected to increase.

Dr Satu Vainikka, CEO, commented: “I am delighted we have received the US patent office’s approval for our gene biomarkers’ activity. This grant significantly strengthens our patent portfolio and it is a particularly pleasing endorsement, coming as it does from under the rigorous scrutiny of the US patent authorities. I am very pleased by the continuing validation of our technologies and of our approach to therapeutics and biomarkers themselves and I believe this patent grant further underlines the importance of a genetic approach to the management and detection of oncological diseases.”

For more information, please contact:

ValiRx plc Tel: +44 (0) 20 3008 4416

Dr Satu Vainikka www.ValiRx.com

Cairn Financial Advisers LLP (Nominated Adviser) Tel:+44 (0) 20 7148 7900

Liam Murray / Avi Robinson

Hybridan LLP (Broker) Tel: +44 (0) 20 7947 4350

Claire Noyce / Deepak Reddy

Peckwater PR Tel: +44 (0)7879 458 364

Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk

Background on Biomarkers (Sources: BCC Research and researchandmarkets 2010/2011) Biomarkers in Cancer Research 2010 stated that the use of Biomarkers in Oncology Therapeutics is one of the biggest application areas with main emphasis on predictive and personalized medicine.

The global cancer biomarkers market for 2007 was estimated to be $3.6 billion and is expected to grow at a CAGR (Compounded Annual Growth Rate) of 6.3% to reach $6.3 billion by 2016.

This growth is primarily attributed to the rise in the number of biomarker tests in a wide variety of Cancer types.

In the future, the growth of personalized medicines and the strong support from regulatory agencies such as the FDA will be the two major factors that will drive the demand for biomarkers, particularly in cancer research.

Personalized medicines are gaining popularity due to their ability to provide customized treatment to patients based on their genetic as well as medical profile. Since biomarkers help in predicting patient response to a compound, personalized medicine are increasingly using biomarkers to identify the patient population set that is more likely to respond to a particular drug therapy. Personalized medicines are also increasingly being used in targeted cancer therapies. Thus, going forward, as personalized medicines gain more importance and popularity, the demand for biomarkers is also expected to increase.

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

- ValiMedix is the sales and distribution division of ValiRx

- ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES